Lakewood-Amedex Reports Q2 Loss, Unremediated Material Weaknesses, and $1.17M Phase 2a Commitments
LABT sits 37% above its 52-week low of $1.66 on light trading volume (0.2× avg).
Summary
Lakewood-Amedex's Q2 10-Q shows a $4.7M H1 net loss, unremediated material weaknesses in internal controls, and new $1.17M clinical trial commitments, while the placement agency agreement was terminated.
Key Events · Earnings and Guidance · LABT
-
Going Concern Warning Persists
The company reported a net loss of $4.7 million for the six months ended June 30, 2026, and management concluded that substantial doubt about its ability to continue as a going concern remains, with cash runway only into Q1 2027.
-
Material Weaknesses Unremediated
Disclosure controls and procedures were not effective as of June 30, 2026 due to material weaknesses including limited segregation of duties, insufficient management review controls over investments, EPS, stock-based compensation, income taxes, and lease accounting, and ineffective IT general controls.
-
Phase 2a Trial Commitments
The company entered into clinical manufacturing and research agreements totaling approximately $1.17 million in estimated costs for the Phase 2a trial of Nu-3, with $783,717 remaining to be incurred as of June 30, 2026.
-
Placement Agency Agreement Terminated
The agreement with RBW Capital Partners LLC was terminated effective August 6, 2026, following written notice on July 8, 2026, removing a key financing intermediary.
Analysis · LABT · Life Sciences
The 10-Q confirms the company's going concern warning remains in place, with a net loss of $4.7 million for the first half of 2026 and cash runway only into Q1 2027. More importantly, management discloses that material weaknesses in internal controls — including limited segregation of duties and insufficient review over key accounting areas — remain unremediated as of June 30, 2026. The company also committed to approximately $1.17 million in clinical manufacturing and research agreements for its Phase 2a trial of Nu-3, signaling a shift from financing to execution. The termination of the placement agency agreement with RBW Capital Partners effective August 6, 2026 removes a key financing intermediary, potentially complicating future capital raises.
At the time of this filing, LABT was trading at $2.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $1.66 to $98.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.